Sign in
Enrolling by invitationNo phase

Follows hip replacement patients using the G7 Freedom Constrained Vivacit-E liner

Studies a hip replacement liner device in adults with hip arthritis or fracture.

Key facts

Who runs it
Zimmer Biomet
Where
Birmingham, Columbus, Gainesville, Houston, Knoxville, Livingston, Los Angeles, Morgantown, Plano, and Salt Lake City, United StatesSee the 10 sites
Trial code
Registry title
G7 Freedom Constrained Vivacit-E Liners
Status
Enrolling by invitation
People taking part
202 people, planned
Started
8 May 2023
Expected to end
Dec 2038
Type of study
Interventional
Treatments tested
  • Total Hip Arthroplasty with G7 Freedom Constrained Vivacit-E Liners
Record updated
20 October 2025

Who can take part

AI summary

From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.

The trial is looking for adults who need a total hip replacement on one side. It follows the long-term safety and performance of the G7 Freedom Constrained Vivacit-E hip liner.

Age
18 to 80 years old, and skeletally mature.
Sex
Men and women can join.
Disease stage
Needs a one-sided total hip replacement (first or revision) for at least one reason: osteoarthritis or avascular necrosis, rheumatoid arthritis, high risk of hip dislocation, revision surgery, correcting a functional deformity, or a non-union, femoral neck or trochanteric fracture that other techniques cannot manage.
Earlier treatment
No hip replacement on the other side within 3 months before this surgery, and none planned within 3 months after it.

Main reasons for not taking part

  • Active infection, sepsis or bone infection (osteomyelitis) in the affected joint
  • Significant osteoporosis, osteomalacia or a metabolic disorder that may impair bone formation
  • Both hips replaced in the same surgery
  • Known pregnancy
  • Prisoner, known alcohol or drug abuser, or unable to understand what taking part involves

The registry criteria, word for word

Show all 17 criteriaShow less

Who can take part

  • Patient is 18 to 80 years of age, inclusive
  • Patient is skeletally mature
  • Patient qualifies for unilateral total hip arthroplasty based on physical exam and medical history including at least one of the following:; Non-inflammatory degenerative joint disease, including osteoarthritis and avascular necrosis; Rheumatoid arthritis; High risk for dislocation; Undergoing revision hip arthroplasty; Correction of functional deformity; In need of treatment of non-union, femoral neck fracture, and trochanteric fractures of the proximal femur with head involvement, unmanageable by other techniques
  • Patient is willing and able to complete scheduled follow-up evaluations as described in the protocol and Informed Consent
  • Patient, or the patient's legally authorized representative, has participated in the Informed Consent process and is willing and able to sign an IRB approved informed consent

Who cannot take part

  • In the opinion of the investigator, patient has any concomitant disease which is likely to jeopardize the functioning or success of the implant
  • The patient is in the vulnerable population group, such as; a prisoner; a known alcohol or drug abuser; mentally incompetent or unable to understand what participation in this study entails
  • Patient is septic, has an active infection or has osteomyelitis at the affected joint
  • Patient has metabolic disorder(s) which may impair bone formation
  • Patient has distant foci of infections which may spread to the implant site
  • Patient has vascular insufficiency, muscular atrophy at the implant site or neuromuscular disease which might jeopardize the outcome of the surgery
  • Patient has significant osteoporosis as defined by treating surgeon
  • Patient has osteomalacia
  • Patient has rapid joint destruction, marked bone loss or bone resorption on pre-operative radiographs
  • Patient underwent contralateral THA within 3 months of planned index procedure or has a contralateral THA planned within 3 months of the index procedure
  • Patient is undergoing simultaneous bilateral THA
  • Patient is known to be pregnant

Check if you might fit

Answer for yourself. This is not a decision: only the study team can say whether you can take part.

  • Are you between 18 and 80 years old?

Where in United States

  • University of Alabama at BirminghamBirmingham, United StatesEnrolling by invitation
  • The Ohio State UniversityColumbus, United StatesEnrolling by invitation
  • University of Florida Board of TrusteesGainesville, United StatesEnrolling by invitation
  • The University of Texas Health Science Center of HoustonHouston, United StatesEnrolling by invitation
  • TOA Research FoundationKnoxville, United StatesEnrolling by invitation
  • Jersey City Medical Center, IncLivingston, United StatesEnrolling by invitation
  • University of Southern CaliforniaLos Angeles, United StatesEnrolling by invitation
  • West Virginia UniversityMorgantown, United StatesEnrolling by invitation
  • Medical City PlanoPlano, United StatesEnrolling by invitation
  • University of UtahSalt Lake City, United StatesEnrolling by invitation

About the trial

What the trial wants to find out

The main objectives of this study are to confirm the long-term safety, performance, and clinical benefits of the G7 Freedom Constrained Vivacit-E Acetabular Liners in primary and revision total hip arthroplasty.

The group in the trial

  • Total Hip Arthroplasty Treatment GroupTreatment being tested

    This study will enroll (implant) up to 202 hips in total according to the IFU and surgical technique. Of these, up to 135 will be revision hips and up to 67 will be primary hips. This is a dual cohort study (primary and revision); each subject will receive the G7 Acetabular System with the Freedom Constrained Vivacit-E bearing. To minimize potential bias and to maximize our ability to assess inter-site differences, each study site will target up to 27 primary hip arthroplasties and up to 54 revision hip arthroplasties (not exceed 81 implanted hips or 40% of total study population). Each site is encouraged to enroll (implant) both primary and revision subjects.

    Treatment: Total Hip Arthroplasty with G7 Freedom Constrained Vivacit-E Liners

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Print a page for my doctor

Data and sources

Registry record
Listed on ClinicalTrials.gov.
Official title
Multicenter, Prospective Post-Market Clinical Follow-Up Study of the G7® Freedom Constrained Vivacit-E® Liners
Plain-language title
Follows hip replacement patients using the G7 Freedom Constrained Vivacit-E linerGenerated from the registry record. The registry title is the official one.
AI summary
From the trial's eligibility criteria. Read by machine on 12 November 2026.
Fit questions
Built from NCT05587244, who can take part
Record updated
20 October 2025